Keros Therapeutics (KROS) Director Bienaime Buys 1,000 Shares

What Happened
BIENAIME JEAN JACQUES, a director of Keros Therapeutics, acquired 1,000 shares in an open‑market purchase (transaction code P) on August 17, 2026. The reported weighted average price was $10.27 per share, for a total transaction value of approximately $10,270. This was a purchase (an incoming cash investment), not a sale.

Key Details

• Transaction date: August 17, 2026; filing date: August 19, 2026 (filed within the Form 4 two‑business‑day requirement).
• Shares acquired: 1,000; weighted average price reported: $10.27; total value ≈ $10,270.
• Price range: purchases occurred at prices between $10.02 and $10.39 (inclusive); the filer can provide a breakdown of shares bought at each price on request (footnote).
• Plan note: the purchases were made pursuant to a Rule 10b5‑1 trading plan adopted by the reporting person on December 5, 2025.
• Shares owned after the transaction: not disclosed in the filing.

Context
Purchases by insiders can be informative to investors, but this trade was executed under a pre‑set 10b5‑1 plan, which may reflect scheduled trading rather than a new view on the company. The filing is a routine Form 4 reporting the acquisition; it does not state the insider’s broader holdings or intent.